QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - Investors in uniQure N.V. have the opportunity to lead a securities fraud lawsuit against the company due to alleged violations of the Securities Exchange Act of 1934, specifically related to misleading statements about FDA approval and BLA timelines [1] Group 1: Lawsuit Details - The Schall Law Firm is reminding investors of a class action lawsuit against uniQure N.V. for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 [1] - The class period for the lawsuit is defined as between September 24, 2025, and October 31, 2025, during which investors are encouraged to contact the firm before April 13, 2026 [1] - The lawsuit claims that uniQure made false and misleading statements regarding its ability to secure full FDA approval for its Pivotal Study and misrepresented the likelihood of delaying its BLA timeline [1] Group 2: Investor Impact - Investors who purchased uniQure's securities during the class period reportedly suffered damages when the truth about the company's misleading statements was revealed [1] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally, indicating a focus on protecting shareholder rights [1]